This company has been marked as potentially delisted and may not be actively trading. GlycoMimetics (CBIO) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsDividendSustainabilityTrendsBuy This Stock CBIO vs. OPK, GERN, RGLS, ZBIO, MYGN, RIGL, EBS, VSTM, XOMA, and VNDAShould you be buying GlycoMimetics stock or one of its competitors? The main competitors of GlycoMimetics include OPKO Health (OPK), Geron (GERN), Regulus Therapeutics (RGLS), Zenas Biopharma (ZBIO), Myriad Genetics (MYGN), Rigel Pharmaceuticals (RIGL), Emergent BioSolutions (EBS), Verastem (VSTM), XOMA (XOMA), and Vanda Pharmaceuticals (VNDA). These companies are all part of the "biotechnology" industry. GlycoMimetics vs. Its Competitors OPKO Health Geron Regulus Therapeutics Zenas Biopharma Myriad Genetics Rigel Pharmaceuticals Emergent BioSolutions Verastem XOMA Vanda Pharmaceuticals GlycoMimetics (NASDAQ:CBIO) and OPKO Health (NASDAQ:OPK) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, community ranking, earnings, media sentiment, analyst recommendations and profitability. Is CBIO or OPK more profitable? GlycoMimetics has a net margin of 0.00% compared to OPKO Health's net margin of -5.66%. OPKO Health's return on equity of -2.85% beat GlycoMimetics' return on equity.Company Net Margins Return on Equity Return on Assets GlycoMimeticsN/A -293.92% -206.20% OPKO Health -5.66%-2.85%-1.82% Do institutionals & insiders have more ownership in CBIO or OPK? 75.2% of GlycoMimetics shares are owned by institutional investors. Comparatively, 64.6% of OPKO Health shares are owned by institutional investors. 8.7% of GlycoMimetics shares are owned by insiders. Comparatively, 49.7% of OPKO Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media favor CBIO or OPK? In the previous week, GlycoMimetics had 9 more articles in the media than OPKO Health. MarketBeat recorded 9 mentions for GlycoMimetics and 0 mentions for OPKO Health. OPKO Health's average media sentiment score of 0.34 beat GlycoMimetics' score of 0.00 indicating that OPKO Health is being referred to more favorably in the news media. Company Overall Sentiment GlycoMimetics Neutral OPKO Health Neutral Does the MarketBeat Community prefer CBIO or OPK? OPKO Health received 204 more outperform votes than GlycoMimetics when rated by MarketBeat users. However, 68.36% of users gave GlycoMimetics an outperform vote while only 65.60% of users gave OPKO Health an outperform vote. CompanyUnderperformOutperformGlycoMimeticsOutperform Votes30968.36% Underperform Votes14331.64% OPKO HealthOutperform Votes51365.60% Underperform Votes26934.40% Do analysts prefer CBIO or OPK? OPKO Health has a consensus target price of $2.75, suggesting a potential upside of 113.18%. Given OPKO Health's stronger consensus rating and higher probable upside, analysts plainly believe OPKO Health is more favorable than GlycoMimetics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GlycoMimetics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00OPKO Health 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has better earnings & valuation, CBIO or OPK? GlycoMimetics has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than GlycoMimetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGlycoMimetics$10K862.55-$37.88M-$1.38-9.62OPKO Health$713.10M1.43-$53.22M-$0.07-18.43 Which has more volatility & risk, CBIO or OPK? GlycoMimetics has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500. SummaryOPKO Health beats GlycoMimetics on 10 of the 18 factors compared between the two stocks. Get GlycoMimetics News Delivered to You Automatically Sign up to receive the latest news and ratings for CBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CBIO vs. The Competition Export to ExcelMetricGlycoMimeticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.63M$2.50B$5.33B$8.57BDividend YieldN/A1.53%5.32%4.20%P/E Ratio-0.299.5325.9719.02Price / Sales862.55525.68419.64156.40Price / CashN/A165.1935.6355.74Price / Book1.615.047.825.05Net Income-$37.88M$37.71M$3.15B$249.31M GlycoMimetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CBIOGlycoMimetics0.6434 of 5 stars$13.27-16.0%N/AN/A$8.63M$10K-0.297News CoverageStock SplitOPKOPKO Health4.4679 of 5 stars$1.38-0.4%$2.75+100.0%+3.2%$1.09B$689.41M-7.244,200Positive NewsGERNGeron3.1698 of 5 stars$1.61-0.9%$5.06+215.4%-69.0%$1.02B$116.29M-5.0270Positive NewsRGLSRegulus Therapeutics1.5476 of 5 stars$8.26-0.5%$8.50+3.0%+246.0%$571.53MN/A-7.7130Positive NewsZBIOZenas Biopharma1.4339 of 5 stars$12.20+2.3%$36.67+200.5%N/A$510.38M$15M-3.44N/AGap UpMYGNMyriad Genetics4.0373 of 5 stars$5.20+0.1%$14.38+176.9%-79.3%$479.78M$831.30M-4.002,600RIGLRigel Pharmaceuticals3.7352 of 5 stars$22.25+1.8%$36.40+63.6%+106.8%$397.56M$203.08M158.90160Positive NewsEBSEmergent BioSolutions4.4305 of 5 stars$6.74+3.9%$14.33+112.6%+3.9%$366.59M$930.30M-1.652,420Positive NewsVSTMVerastem3.2021 of 5 stars$6.25+2.3%$13.63+118.0%+53.0%$342.55M$10M-1.9550XOMAXOMA4.1158 of 5 stars$25.16-0.5%$69.50+176.3%-1.1%$299.85M$13.05M-7.2010VNDAVanda Pharmaceuticals4.6758 of 5 stars$4.63+0.8%$16.50+256.7%-29.3%$273.10M$201.35M-14.48290 Related Companies and Tools Related Companies OPKO Health Competitors Geron Competitors Regulus Therapeutics Competitors Zenas Biopharma Competitors Myriad Genetics Competitors Rigel Pharmaceuticals Competitors Emergent BioSolutions Competitors Verastem Competitors XOMA Competitors Vanda Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CBIO) was last updated on 6/18/2025 by MarketBeat.com Staff From Our PartnersWhat 99% of investors are missing about Chinese AIChinese AI chatbot DeepSeek's release put the spotlight on AI and turned the tech world on its head. But 99...Weiss Ratings | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored72 Hours Until Musk’s $34 Trillion AI Network BeginsIn just 72 hours, Elon Musk is expected to flip the switch on Tesla’s autonomous network in Austin, Texas. ...The Oxford Club | SponsoredSorry about the swear wordWhat a huge few months for Bitcoin. First, Bitcoin hit $100,000… Then, Donald Trump pledged to create an...Manward Press | SponsoredPresident Trump Could Soon Unlock Trillions in New WealthIf you think America is broke, think again. These "reserve accounts" are worth trillions... And according t...InvestorPlace | SponsoredGold Just Jumped Again. Here’s How to Get PaidGold prices just spiked again. As I write this, gold is trading near $3,400 an ounce. But here's the thi...Investors Alley | SponsoredThe Dollar Reset Nobody’s Talking AboutCould this man take down the financial system? In March, the Senate granted sweeping powers to a Harvard ec...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlycoMimetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GlycoMimetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CBIO Stock Free CBIO Stock Alerts